Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

RTI-112

From Wikipedia, the free encyclopedia
Synthetic stimulant and triple reuptake inhibitor
This articlemay be too technical for most readers to understand. Pleasehelp improve it tomake it understandable to non-experts, without removing the technical details.(August 2009) (Learn how and when to remove this message)
Pharmaceutical compound
RTI-112
Identifiers
  • Methyl (1R,2S,3S,5S)-3-(4-chloro-3-methylphenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H22ClNO2
Molar mass307.82 g·mol−1
3D model (JSmol)
  • CC1=C(C=CC(=C1)[C@H]2C[C@@H]3CC[C@H]([C@H]2C(=O)OC)N3C)Cl
  • InChI=1S/C17H22ClNO2/c1-10-8-11(4-6-14(10)18)13-9-12-5-7-15(19(12)2)16(13)17(20)21-3/h4,6,8,12-13,15-16H,5,7,9H2,1-3H3/t12-,13+,15+,16-/m0/s1 ☒N
  • Key:VMITZEMDDZVHBZ-XNISGKROSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

RTI(-4229)-112 (2β-carbomethoxy-3β-(3-methyl-4-chlorophenyl)tropane) is a syntheticstimulant drug from thephenyltropane family. It is primarily used in scientific research to study the brain'sreward system. In contrast to more well-known stimulants that primarily affect one type of brain cell communication, RTI-112 is a nonselectivetriple reuptake inhibitor. This means it simultaneously affects three important brain chemicals:serotonin,dopamine, andnorepinephrine.[1]

In vitro tests show a very similarserotonin transporter (SERT)/dopamine transporter (DAT)/norepinephrine transporter (NET) selectivity tococaine,[2] although in vivo behaviour is different:

"Thenonselective monoamine transporter inhibitorRTI-126 and the DAT-selective inhibitorsRTI-150 andRTI-336 both had a faster rate of onset (30 min) and a short duration of action (4h). In contrast, the nonselective monoamine transporter inhibitor RTI-112 had a slower rate of onset (30–60 min) and a longer duration of action (10h). The DAT-selective inhibitorsRTI-171 andRTI-177 also had slower rates of onset (30–120 min), but RTI-171 had a short duration of action (2.5 h) whileRTI-177 had a very long duration of action (20 h)."[3]

The efficacy of cocaine analogs to elicit self-administration is related to the rate at which they are administered.[clarification needed] Slower onset analogs are less likely to function as behavioral stimulants than analogs eliciting a faster rate of onset.[4] Nonselective analogs are less likely to function as "reinforcers" than reuptake inhibitors that have DAT specificity.[3]

In order for adopamine reuptake inhibitor (DRI) such as cocaine to induce euphoria,PET scans on primates reveal that the DAT occupancy needs to be >60%.[5]

RTI-112 has equipotent in vitro affinity at the SERT, NET and DAT, respectively.[2] RTI-112 was not reliably self-administered, in contrast to the DAT selective reuptake inhibitors that were used in this study.[2]

In vivo at the ED50, RTI-112 had no DAT occupancy at all.[2] At the ED50, almost all of the RTI-112 occupied the SERT at this dose.[2] A significantly higher dose was required to get >70% DAT occupancy in the case of RTI-112;[2] however, RTI-112 was still able to suppress cocaine administration at the ED50, suggesting a serotonergic mechanism was responsible for this.[2]

References

[edit]
  1. ^Ginsburg BC, Kimmel HL, Carroll FI, Goodman MM, Howell LL (March 2005)."Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys"(PDF).Pharmacology, Biochemistry, and Behavior.80 (3):481–491.doi:10.1016/j.pbb.2005.01.004.PMID 15740791.S2CID 10004289. Archived fromthe original(PDF) on 2010-06-11.
  2. ^abcdefgLindsey KP, Wilcox KM, Votaw JR, Goodman MM, Plisson C, Carroll FI, et al. (June 2004)."Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging"(PDF).The Journal of Pharmacology and Experimental Therapeutics.309 (3):959–969.doi:10.1124/jpet.103.060293.PMID 14982963.S2CID 39794215. Archived fromthe original(PDF) on 2010-06-11. Retrieved2009-07-15.
  3. ^abKimmel HL, O'Connor JA, Carroll FI, Howell LL (January 2007)."Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys".Pharmacology, Biochemistry, and Behavior.86 (1):45–54.doi:10.1016/j.pbb.2006.12.006.PMC 1850383.PMID 17258302.
  4. ^Wee S, Carroll FI, Woolverton WL (February 2006)."A reduced rate of in vivo dopamine transporter binding is associated with lower relative reinforcing efficacy of stimulants".Neuropsychopharmacology.31 (2):351–362.doi:10.1038/sj.npp.1300795.PMID 15957006.
  5. ^Howell LL, Wilcox KM (July 2001)."The dopamine transporter and cocaine medication development: drug self-administration in nonhuman primates"(PDF).The Journal of Pharmacology and Experimental Therapeutics.298 (1):1–6.doi:10.1016/S0022-3565(24)29344-7.PMID 11408518. Archived fromthe original(PDF) on 2006-09-21.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
2-Carboxymethyl Esters
(3,4-Disubstituted Phenyl)-tropanes
Arylcarboxy
Carboxyalkyl
Acyl
β,α Stereochemistry
α,β Stereochemistry
Heterocycles: 3-Substituted-isoxazol-5-yl
Heterocycles: 3-Substituted-1,2,4-oxadiazole
N-alkyl
N-replaced (S,O,C)
Irreversible
Nortropanes (N-demethylated)
Retrieved from "https://en.wikipedia.org/w/index.php?title=RTI-112&oldid=1300905024"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp